10.3389/fphar.2024.1342831 213
Cooper's licensed care team the same high standard of care at every clinic
Nausea: the most common side effect Nausea affects 20-50% of semaglutide users, making it by far the most frequently reported side effect
This includes: Complete blood panel Hormone level assessment Organ function tests Cardiovascular evaluation Safety Protocol Requirements : Regular blood glucose monitoring Periodic liver function tests Quarterly health assessments Ongoing cardiovascular monitoring The power of IGF-1 LR3 demands respect and careful attention to these safety protocols
Practical Guidance If you choose to drink on a GLP-1 medication: Keep intake to 1 standard drink (5 oz wine, 12 oz beer, 1.5 oz spirits) maximum on any given day Never drink on an empty stomach pair alcohol with a protein-containing meal Drink water before, during, and after 1:1 ratio Never combine alcohol with insulin or sulfonylurea medications without extra caution Avoid sweetened cocktails (double impact: alcohol + sugar) Do not drink on the day of a dose increase side effects are worst that week The safest recommendation is to eliminate alcohol entirely during active weight loss on a GLP-1

Safety Profile: What We Learned About Side Effects Common Adverse Events The TRIUMPH-4 trial confirmed that retatrutide's side effect profile aligns with other incretin-based therapies, with gastrointestinal symptoms being the most common: Incidence of GI Side Effects (12mg dose): Nausea: 43% (vs 11% placebo) Diarrhea: 33% (vs 13% placebo) Vomiting: 21% (vs 0% placebo) Constipation: Elevated vs placebo Decreased appetite: Common Most gastrointestinal side effects were mild to moderate in severity and occurred primarily during the dose escalation phase